1130 Clinical Outcomes of Sacral Nerve Stimulation for Neuromodulation of the Lower Urinary Tract in a Tertiary Hospital

Aim To assess clinical outcomes in terms of first to second stage conversion rates, revision rates , complications, battery life span and device survival for all patients undergoing sacral neuromodulation for the past 5 years at the Queen Elizabeth hospital Birmingham. Method Retrospective observational study. Only patients who had first stage of sacral neuromodulation between January 2017 and January 2023 were included in the study. The data collected included age, type of first stage i.e PNE vs tined lead, response after first stage, if a second trial was carried out, response after second trial, indication for SNS, complications, revisions, etc. Results 94% of the total (198 ) patients had PNE at first trial while 6% had tined lead. 130 patients had a positive response after first trial, 48 had a negative response and 20 had equivocal response. 15 patients from the equivocal group had a second trial with tined lead with 53.3% receiving a positive response making our conversion rate 69% . Of the 100 patients who had permanent implant fitted, only 18 had complications and 14 of these required revision. The indications for the revision were lead migration (36%), connection failure (14%), battery charging problem (7%), pain around battery site (36%) and device infection (7%). Conclusions The conversion and complication rates are comparable to national standards while the infection rates were lower than what has been reported in the literature. Higher conversion rates may be attained when tined lead is used at first trial.